DB15430Investigational
Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
- Mechanism
- Curator reviewed
Pharmacologically active on Receptor tyrosine-protein kinase erbB-3
- Code names
- LJM716
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Elgemtumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account